Meredith Ian T. - 01 Feb 2022 Form 4 Insider Report for BOSTON SCIENTIFIC CORP (BSX)

Role
EVP Global Chief Med Officer
Signature
/s/ Vance R. Brown, Attorney-in-fact
Issuer symbol
BSX
Transactions as of
01 Feb 2022
Net transactions value
-$39,976
Form type
4
Filing time
02 Feb 2022, 15:37:25 UTC
Previous filing
03 Jan 2022
Next filing
17 Feb 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BSX Common Stock Options Exercise $0 +3,131 +11% $0.000000 31,758 01 Feb 2022 Direct F1
transaction BSX Common Stock Tax liability $39,976 -919 -2.9% $43.50 30,839 01 Feb 2022 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BSX Deferred Stock Units Options Exercise $0 -3,131 -100% $0.000000* 0 01 Feb 2022 Common Stock 3,131 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.
F2 Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 1, 2018, the first anniversary of the date of grant.

Remarks:

meredithpoa.txt